Metanx in Type 2 Diabetes with Peripheral Neuropathy: A Randomized Trial Vivian A. Fonseca, MD, Lawrence A. Lavery, DPM, MPH, Tina K. Thethi, MD, Yahya Daoud, PhDC, Cyrus DeSouza, MD, Fernando Ovalle, MD, Douglas S. Denham, DO, Teodoro Bottiglieri, PhD, Peter Sheehan, MD, Julio Rosenstock, MD The American Journal of Medicine Volume 126, Issue 2, Pages 141-149 (February 2013) DOI: 10.1016/j.amjmed.2012.06.022 Copyright © 2013 Elsevier Inc. Terms and Conditions
Figure 1 Change in mean Neuropathy Total Symptom Score (NTSS-6) from baseline to 24 weeks. This questionnaire includes 6 yes-or-no questions about neuropathic symptoms including various types of pain, tingling, and loss of sensation. Each “yes” answer is scored as 1 point. Lower scores signify improvement. The American Journal of Medicine 2013 126, 141-149DOI: (10.1016/j.amjmed.2012.06.022) Copyright © 2013 Elsevier Inc. Terms and Conditions